biostudies-literatureGriffiths EANCI NIH HHS590-600https://www.ebi.ac.uk/biostudies/studies/S-EPMC3052845biostudies-literatureUnknown5(7)<h4>Background</h4>Methylation of tumor suppression genes (TSGs) is common in myeloid malignancies. However, application of this as a molecular marker for risk stratification in patients with AML is limited.<h4>Design and methods</h4>To elucidate the impact of patterns of TSG methylation on outcome in cytogenetically normal patients, 106 samples from patients with having normal cytogenetic AML were evaluated for methylation of 12 genes by MSP. For sake of comparison, samples from patients with AML and abnormal cytogenetics (n = 63) were also evaluated.<h4>Results</h4>Methylation frequencies in the whole group (n = 169) were similar to previous reports for CDH1 (31%), ER (31%), FHIT (9%), p15 (INK4b) (44%), p73 (25%), and SOCS1 (75%). Methylation of CTNNA1 was observed in 10%, CEBP-α in16%,EpigeneticsEpigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia.PMC3052845K24 CA111717CA06793McDevitt MAKarp JEHooker CMMohammad HPSmith BDCarraway HEHerman JGGriffiths EAGore SDfalseEpigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia.<h4>Background</h4>Methylation of tumor suppression genes (TSGs) is common in myeloid malignancies. However, application of this as a molecular marker for risk stratification in patients with AML is limited.<h4>Design and methods</h4>To elucidate the impact of patterns of TSG methylation on outcome in cytogenetically normal patients, 106 samples from patients with having normal cytogenetic AML were evaluated for methylation of 12 genes by MSP. For sake of comparison, samples from patients with AML and abnormal cytogenetics (n = 63) were also evaluated.<h4>Results</h4>Methylation frequencies in the whole group (n = 169) were similar to previous reports for CDH1 (31%), ER (31%), FHIT (9%), p15 (INK4b) (44%), p73 (25%), and SOCS1 (75%). Methylation of CTNNA1 was observed in 10%, CEBP-α in16%,2010-01-01T00:00:00Z2010 Oct2025-04-04T01:33:58.991Z2019-03-27T00:39:30ZS-EPMC30528452067142710.4161/epi.5.7.12558